Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs
Increasingly Crowded Field
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
You may also be interested in...
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.